Akari Therapeutics, Plc
22 Boston Wharf Road, FL 7
Boston, MA 02210
May 12, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-7553
Re: Akari Therapeutics, Plc
Registration Statement on Form S-3
Filed May 6, 2025 (File No. 333-287012)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-287012) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:05 P.M., Eastern Time, on May 14, 2025, or as soon thereafter as is practicable.
Please contact Sam Zucker, Esq. of Goodwin Procter LLP, counsel to the Company, at (650) 752-3232 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
[Remainder of the page intentionally left blank]